DGAP-News: ifa systems AG / Key word(s): Annual Results/Preliminary Results
According to preliminary figures, ifa systems AG, a listed specialist for health IT applications in ophthalmology, increased its sales to € 9.7 million in the 2019 fiscal year (previous year: € 6.6 million). The licensing of the database of the American subsidiary in the amount of € 2.5 million had a decisive influence on the strong increase. Adjusted for this effect, growth amounted to 7.8 percent. The operating result (EBITDA) tripled to € 3.9 million. EBIT reached € 1.2 million (previous year: € 0.1 million) after depreciation in the amount of € 2.7 million, € 1.4 million of which was due to impairment of intangible assets as a result of the portfolio valuation after the takeover of the majority interest by NEXUS AG. Operating cash flow also developed positively as planned and amounted to € 3.4 million. Financial liabilities were halved to € 3.0 million.
"The past business year was extraordinarily successful in every respect", says Jörg Polis, CEO of ifa systems AG. "Sales and profitability have developed at the upper end of expectations. At the same time the balance sheet was strengthened. We can be very satisfied with what we have achieved".
Financial year 2020
Sales and earnings in 2019 were significantly influenced by special effects. The introduction of the telematics infrastructure has largely been completed and similar revenues from the licensing of the database of the American subsidiary Inoveon cannot be budgeted for the fiscal year 2020. They would always represent a non-recurring effect. For the 2020 financial year, the Management Board therefore expects only moderate growth in revenue from current business and a positive operating result (EBIT). Further details of the forecast will be published with the annual report probably on April 27, 2020.
Publication of the Annual Report April 28, 2020
Spring Conference May 18 - 20, 2020
Annual General Meeting June 5, 2020
Contact for further inquiries:
ifa systems AG
50226 Frechen (Germany)
+49 2234 933 670
With over 30 years of experience, ifa systems AG is one of the world's leading providers of software solutions in ophthalmology. The focus of the company's activities is on the development of an electronic health record (EHR) tailored to the needs of ophthalmology. ifa's EHR, in which all details of examinations and treatments are documented and managed, can be used flexibly in specialist practices and eye centers as well as in specialized departments of hospitals. The range of services also includes supplementary software products for networking ophthalmological diagnostic devices. With its innovative product portfolio, ifa makes a decisive contribution to ensuring the optimal treatment of patients and supports the simplification of procedures for doctors and medical staff. With the products and solutions of ifa systems AG, people worldwide work in more than 20 countries at a total of more than 15,000 workplaces, treating more than 200,000 clinical patient cases every day. According to experts, this niche market will grow to a volume of over 6.2 billion US dollars by 2020. ifa systems AG is listed on the Open Market of the Frankfurt Stock Exchange with ISIN DE 007830788. NEXUS AG holds more than 50% of the shares and is also listed on the stock exchange (ISIN DE0005220909).
|Company:||ifa systems AG|
|Augustinusstraße 11 b|
|Phone:||+49 (0)2234 93367-0|
|Fax:||+49 (0)2234 93367-30|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||991231|
|End of News||DGAP News Service|